Researchers conducted the UP-TAINED study to assess the effectiveness and safety of upadacitinib for over 2 years, with patients with moderate to severe AD receiving either 15 mg or 30 mg once daily.
Clinical Trials Arena on MSN
J&J’s Spravato touts durable anti-depressant benefits in real-world study
J&J’s Tamara Werner-Kiechle tells Clinical Trials Arena that the depression landscape needs reframing to ensure optimal ...
Mepolizumab significantly reduced asthma exacerbations and oral corticosteroid use in patients with SEA, with or without CRSwNP, in a real-world setting. Improvements in lung function and asthma ...
Sensitive skin affects up to 70% of people globally – a figure that has risen by 68% over the past two decades – yet it remains widely overlooked and under-studied. 2,3 As more people live fast-paced ...
Brentuximab vedotin with CHP is effective and safe for first-line PTCL treatment, achieving an 80% overall response rate. Median progression-free survival was 39.7 months, with a 1-year overall ...
PointClickCare, a leading health tech company helping providers deliver exceptional care, today announced the launch of Study ...
TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (BIIB) (Nasdaq ...
Real-world studies assess treatment effectiveness and patient experience beyond clinical trial settings, considering broader patient populations. Clinical trials have stricter enrollment criteria, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results